NCT06108830 Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients
| NCT ID | NCT06108830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University General Hospital |
| Condition | Sleep Disturbance |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2024-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-12-01 with a primary completion date of 2024-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies
Eligibility Criteria
Inclusion Criteria: 1. Age 20-65 years old; 2. ASA classification is grade I-III; 3. Elective surgery is proposed 4. BMI of 19-30 kg/m2; 5. Patients who agreed to enroll in this study voluntarily Exclusion Criteria: 1. Those who are known to be allergic to the drug ingredients in this study and their allergic constitution; 2. Allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs; 3. History of neurological diseases; History of chronic pain; Drug and alcohol addiction; A long history of opioid use; Opiates were given 48 hours before surgery; 4. ASA rating of IV or V; 5. Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities; 6. History of gastrointestinal disease (peptic ulcer, Crohn's disease, ulcerative colitis); 7. Respiratory insufficiency, respiratory failure; 8. Patients who refused to use intravenous PCA for analgesia; 9. Pregnant or lactating women; 10. BMI\<18 kg/m2 or BMI\>30kg/m2; 11. Poor compliance, unable to complete the experiment according to the study plan; 12. Participants who have participated in clinical trials of other drugs within the last 4 weeks; 13. Any circumstances deemed unsuitable for inclusion by the researcher for any reason.
Contact & Investigator
Guolin Wang
STUDY DIRECTOR
Tianjin Medical University General Hospital
Frequently Asked Questions
Who can join the NCT06108830 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 65 Years, studying Sleep Disturbance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06108830 currently recruiting?
Yes, NCT06108830 is actively recruiting participants. Contact the research team at wangguolinghad@hotmail.com for enrollment information.
Where is the NCT06108830 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06108830 clinical trial?
NCT06108830 is sponsored by Tianjin Medical University General Hospital. The principal investigator is Guolin Wang at Tianjin Medical University General Hospital. The trial plans to enroll 400 participants.